Cyclodextrin nanosystems in oral drug delivery: A mini review

Adeoye, Oluwatomide; Cabral-Marques, Helena

doi:10.1016/j.ijpharm.2017.04.050

Cited by 122 publications

(73 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Peyer's patches in gutassociated lymphoid tissue (GALT) are characterized by M-cells and are mostly located in the ileum (Adeoye & Cabral-Marques, 2017;Degim et al, 2006). In this way, the nanoparticles are taken up by the lymphatic system and can pass easily into the systemic circulation and reach the target region by active targeting (Adeoye & Cabral-Marques, 2017;Gmeiner & Ghosh, 2015). In this way, the nanoparticles are taken up by the lymphatic system and can pass easily into the systemic circulation and reach the target region by active targeting (Adeoye & Cabral-Marques, 2017;Gmeiner & Ghosh, 2015).…”

Section: Introductionmentioning

confidence: 99%

“…Peyer's patches are an important absorption pathway for oral nanosystems. The Peyer's patches in gutassociated lymphoid tissue (GALT) are characterized by M-cells and are mostly located in the ileum (Adeoye & Cabral-Marques, 2017;Degim et al, 2006). Nanosized lipid-based systems can target the GALT, thereby facilitating absorption by Peyer's patches, which prevents P-glycoprotein efflux by intestinal epithelial cells (Beloqui, del Pozo-Rodríguez, Isla, Rodríguez-Gascón, & Solinís, 2017).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Çoban

Değim

Yılmaz³

et al. 2019

Drug Development Research

View full text Add to dashboard Cite

The main challenges in treating cancer using chemotherapeutics are insufficient dose at the target site and the development of drug resistance, while higher doses can induce side effects by damaging nontarget tissues. Combinatorial drug therapy may overcome these limitations by permitting lower doses and more specific targeting, thereby mitigating drug resistance and nontarget side effects. Recent reports indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) have anticancer potential and can be used together with conventional chemotherapeutics to improve efficacy and safety. In the present study, imatinib mesylate and dexketoprofen trometamol were selected as model drugs to develop targeted surface-modified liposome and nanocochleate formulations for fibrosarcoma treatment. The physicochemical properties and in vitro efficacy of various formulations were evaluated by measurement of particle size distribution, polydispersity index, zeta potential, encapsulation efficiency, diffusion through Caco-2 cells, and toxicity in culture. Selected formulations were then evaluated in fibrosarcoma-bearing model mice by histopathological observations and tyrosine kinase receptor inhibition assays.The most effective formulation on the fibrosarcoma model was a PEGylated nanocochleate formulation. These findings provide a foundation for developing more effective formulations and chemotherapeutic strategies for the treatment of fibrosarcoma and other types of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Çoban

Değim

Yılmaz³

et al. 2019

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…The application of β‐CD in formulating novel fast disintegrating tablets has been reported (Jacob, Shirwaikar, & Nair, ; Late & Banga, ). An overview on CDs‐based oral drug delivery nanosystems has been reviewed recently (Adeoye & Cabral‐Marques, ).…”

Section: In Drug Delivery Systemsmentioning

confidence: 99%

“…The application of β-CD in formulating novel fast disintegrating tablets has been reported(Jacob, Shirwaikar, & Nair, 2009;Late & Banga, 2010). An overview on CDs-based oral drug delivery nanosystems has been reviewed recently(Adeoye & Cabral-Marques, 2017).10.2 | Modified releaseCDs can be considered as promising modified release carriers as they form inclusion complexes with especially hydrophilic drugs, including protein and peptides in solution as well as in solid state. Hydrophobic derivatives like acylated β-CD and cationic trimethyl-ammonium-β-CD are included in the formulation for prolonged release of drugs.…”

mentioning

confidence: 99%

Cyclodextrin complexes: Perspective from drug delivery and formulation

Jacob

Nair

2018

Drug Development Research

163

View full text Add to dashboard Cite

Cyclodextrins (CDs) have been widely investigated as a unique pharmaceutical excipient for past few decades and is still explored for new applications. They are highly versatile oligosaccharides which possess multifunctional characteristics, and are mainly used to improve the physicochemical stability, solubility, dissolution rate, and bioavailability of drugs. Stability constant, factors affecting complexation, techniques to enhance complexation efficiency, the preparation methods for molecular inclusion complexes and release of guest molecules are discussed in brief. In addition, different CD derivatives and their pharmacokinetics are elaborated. Further, the significance of CD complex in aqueous solubility, dissolution and bioavailability, stability, and taste masking is explained. The recent advancement of CDs in developing various drug delivery systems is enlightened. Indeed, the potential of CDs by means of inclusion complex formation have widen the applicability of these materials in various drug delivery systems including ocular, osmotic, mucoadhesive, transdermal, nasal, and targeted delivery systems. Feasibility studies have been performed on the benefit of these cyclic oligomers as nanocarriers, a strategy that can modify the drugs with improved physicochemical properties. Studies also demonstrated the feasibility of CDs to self-assemble in the form of stable nanoaggregates, which may extend the scope of CDs in drug delivery to the continually expanding list of new drug entities.

show abstract

“…Various studies focused on some recent and encouraging advances in the application of cyclodextrin nanosystems for oral drug delivery. [135][136][137][138] Cyclodextrin in oral drug delivery Improvement of oral bioavailability of poorly aqueous soluble drugs is the most challenging step for the scientists in formulation and development of dosage forms. Cyclodextrins have unique structures with versatile physicochemical properties which lead to enhance the solubility, stability, and bioavailability of drugs in the gastrointestinal tract.…”

Section: Cyclodextrins and Nanotechnologymentioning

confidence: 99%

Untitled

Budhwar¹

2018

AJP

View full text Add to dashboard Cite

Inclusion complexes have various applications in different fields of drug delivery and pharmaceutical industry due to their ability of complexation with guest molecules and enhancement of the physicochemical properties of guest molecules. Cyclodextrins and their derivatives have the ability to encapsulate the bioactive compounds into its cavity and protect these from the environmental conditions, improve the solubility, bioavailability, and other properties also. The aim of this review is to highlight the advantages of cyclodextrins in the enhancement of physicochemical properties of drugs (such as solubility, stability, bioavailability, permeability, and others), different methods for production and various characterization techniques used for evaluation of complexes. Applications of cyclodextrin complexes in pharmaceutical and other fields are also explained here with examples. Thus cyclodextrins, because of their continuing ability to find several novel applications in drug delivery, are expected to solve many problems accompanied with the delivery of different novel drugs through various delivery routes.

show abstract

Cyclodextrin nanosystems in oral drug delivery: A mini review

Cited by 122 publications

References 140 publications

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Cyclodextrin complexes: Perspective from drug delivery and formulation

Untitled

Contact Info

Product

Resources

About